Video content above is prompted by the following:
- What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)?
- What further research is needed to understand optimal sequencing of these therapies better?
